您的位置: 首页 > 农业专利 > 详情页

USE OF EDARAVONE IN ORAL TREATMENT OF OXIDATIVE-STRESS MEDIATED NEURODEGENERATIVE DISORDERS
专利权人:
TREEWAY TW001 B.V.
发明人:
Ronald VAN DER GEEST,Sytske Hyke MOOLENAAR
申请号:
US16733958
公开号:
US20200138712A1
申请日:
2020.01.03
申请国别(地区):
US
年份:
2020
代理人:
摘要:
The present invention relates to the use of a liquid aqueous solution of edaravone in the treatment of an oxidative stress-mediated neurodegenerative disorder in a human patient, said treatment comprising at least once daily oral administration of the liquid edaravone solution to the human patient, to provide a daily dose of 40-120 mg edaravone during an uninterrupted period of at least 10 days. Examples of oxidative stress-mediated neurodegenerative disorders that can be treated in this way include amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), cerebral amyloid angiopathy (CAA), Alzheimer's disease and Parkinson's disease.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充